← Feed

Shenouda Maged

SEC Form 4 insider
Chief Financial Officer · RELMADA THERAPEUTICS, INC. ($RLMD)
1 thesis · first seen Sep 11, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$RLMDSEC Form 4bullish
Shenouda Maged · Chief Financial Officer at RELMADA THERAPEUTICS, INC. · 2h agono track record yet
Long 200,000 shares of RLMD
Bought 200,000 @ $4.22 avg · $843,990 · 2026-09-09

Form 4: Shenouda Maged bought RLMD

Shenouda Maged (Chief Financial Officer at RELMADA THERAPEUTICS, INC.) reported an open-market purchase of 200,000 shares of RLMD at an average $4.22, roughly $843,990, in a Form 4 filed 2026-09-11.

Now $4.429m ago
View filing on SEC.gov →

End of results.